RECORD readjudication rosy for rosiglitazone

A Duke University readjudication of the original trial suggests little difference from the original trial, which did not find an increased CV risk for rosiglitazone.

Source: theHeart.org - August 26, 2013 Category: Cardiology Source Type: news